Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.78 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.78 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082641 | 0.95 | S1PR1 (0.73) | S1PR1S1PR3BCHEACHENR1H4 | |
| SCHEMBL13417221 | 0.88 | S1PR1 (1.00) | S1PR1S1PR3ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL13417080 | 0.88 | S1PR1 (0.78) | S1PR1S1PR3KDM4EMEN1ALDH1A1 | |
| SCHEMBL3813299 | 0.86 | S1PR1 (0.76) | S1PR1S1PR3KDM4EMEN1ALDH1A1 | |
| SCHEMBL4618138 | 0.85 | S1PR1 (0.70) | S1PR1S1PR3 | |
| SCHEMBL13417223 | 0.85 | S1PR1 (1.00) | S1PR1S1PR3 | |
| SCHEMBL16592606 | 0.83 | S1PR1 (0.58) | S1PR1S1PR3ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL13417068 | 0.83 | S1PR1 (1.00) | S1PR1S1PR3KDM4EALDH1A1TP53 | |
| SCHEMBL13416533 | 0.82 | S1PR1 (0.69) | S1PR1S1PR3 | |
| SCHEMBL14926463 | 0.81 | S1PR1 (0.76) | S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1893591-A1 | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS | Novartis AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006131336-A1 | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | SOX18, SIGMAR1, SUCNR1 | S1PR1 13/4885S1PR3 22/4885KDM4E 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.